TREACE MEDICAL CONCEPTS, INC. Financials Treace Medical Concepts, Inc.
Equities
TMCI
US89455T1097
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.65 USD | +2.40% |
|
-4.05% | -16.47% |
| 25/03 | Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction | MT |
| 27/02 | Transcript : Treace Medical Concepts, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 991.1 | 1,276 | 786.4 | 659.6 | - | - |
| Enterprise Value (EV) 1 | 914.8 | 1,247 | 716.2 | 719.7 | 723.2 | 751.8 |
| P/E ratio | -43.3 x | -29.9 x | -15.7 x | -11.5 x | -13.1 x | -14.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 10.5 x | 9 x | 4.2 x | 2.96 x | 2.51 x | 2.18 x |
| EV / Revenue | 9.69 x | 8.79 x | 3.83 x | 3.23 x | 2.75 x | 2.48 x |
| EV / EBITDA | -73.7 x | -52.7 x | -29.4 x | -23.5 x | -37.2 x | -49.5 x |
| EV / FCF | -46 x | -27.4 x | -15.6 x | -24.8 x | -34.4 x | -107 x |
| FCF Yield | -2.18% | -3.65% | -6.43% | -4.03% | -2.9% | -0.93% |
| Price to Book | 10.9 x | 21.1 x | 5.62 x | 5.4 x | 6.43 x | 7.16 x |
| Nbr of stocks (in thousands) | 53,173 | 55,502 | 61,676 | 61,935 | - | - |
| Reference price 2 | 18.64 | 22.99 | 12.75 | 10.65 | 10.65 | 10.65 |
| Announcement Date | 03/03/22 | 07/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 57.36 | 94.42 | 141.8 | 187.1 | 222.8 | 263.1 | 303 |
| EBITDA 1 | - | -12.42 | -23.69 | -24.39 | -30.58 | -19.46 | -15.19 |
| EBIT 1 | - | -16.51 | -34.84 | -51.43 | -57.25 | -47.18 | -41.44 |
| Operating Margin | - | -17.49% | -24.57% | -27.48% | -25.7% | -17.93% | -13.68% |
| Earnings before Tax (EBT) 1 | - | -20.55 | -42.82 | -49.53 | -56.73 | -48.77 | -40.79 |
| Net income 1 | - | -20.75 | -42.82 | -49.53 | -56.75 | -48.69 | -40.72 |
| Net margin | - | -21.97% | -30.19% | -26.47% | -25.47% | -18.5% | -13.44% |
| EPS 2 | -0.1196 | -0.4300 | -0.7700 | -0.8100 | -0.9283 | -0.8108 | -0.7132 |
| Free Cash Flow 1 | - | -19.9 | -45.49 | -46.03 | -29 | -21 | -7 |
| FCF margin | - | -21.07% | -32.07% | -24.6% | -13.02% | -7.98% | -2.31% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 30/03/21 | 03/03/22 | 07/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 21.62 | 33.44 | 29.05 | 29.97 | 33.06 | 49.77 | 42.2 | 41.95 | 40.76 | 62.21 | 49.06 | 49.76 | 49.78 | 73.89 | 58.19 |
| EBITDA 1 | -4.432 | -4.028 | -6.353 | -9.419 | -8.215 | 0.286 | -10.03 | -7.746 | -9.237 | 2.629 | -10.72 | -8.004 | -8.702 | 5.976 | -4.85 |
| EBIT 1 | -5.46 | -5.597 | -8.096 | -11.93 | -11.32 | -3.497 | -13.78 | -13.05 | -17.82 | -6.782 | -18.98 | -16.34 | -17.11 | -4.105 | -16.42 |
| Operating Margin | -25.26% | -16.74% | -27.87% | -39.82% | -34.24% | -7.03% | -32.65% | -31.11% | -43.72% | -10.9% | -38.68% | -32.83% | -34.37% | -5.56% | -28.22% |
| Earnings before Tax (EBT) 1 | -6.418 | -6.619 | -9.036 | -17.23 | -12.13 | -4.412 | -13.45 | -12.27 | -17.52 | -6.281 | -19.13 | -16.62 | -17.08 | -3.372 | -16.25 |
| Net income 1 | -6.418 | -6.619 | -9.036 | -17.23 | -12.13 | -4.412 | -13.45 | -12.27 | -17.52 | -6.281 | -19.13 | -16.62 | -17.08 | -3.372 | -16.25 |
| Net margin | -29.69% | -19.79% | -31.11% | -57.51% | -36.71% | -8.86% | -31.89% | -29.25% | -42.99% | -10.1% | -38.99% | -33.41% | -34.31% | -4.56% | -27.93% |
| EPS 2 | -0.1200 | -0.1200 | -0.1600 | -0.3100 | -0.2200 | -0.0800 | -0.2300 | -0.2000 | -0.2800 | -0.1000 | -0.3028 | -0.2689 | -0.2775 | -0.0809 | -0.2556 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 04/11/21 | 03/03/22 | 05/05/22 | 09/08/22 | 08/11/22 | 07/03/23 | 08/05/23 | 08/08/23 | 09/11/23 | 27/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 60.1 | 63.6 | 92.2 |
| Net Cash position 1 | - | 76.3 | 28.5 | 70.2 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -1.965 x | -3.271 x | -6.069 x |
| Free Cash Flow 1 | - | -19.9 | -45.5 | -46 | -29 | -21 | -7 |
| ROE (net income / shareholders' equity) | - | -44.2% | -55.7% | -49.9% | -45% | -53.5% | -56.7% |
| ROA (Net income/ Total Assets) | - | -22.7% | -28.6% | -24.1% | -18.7% | -16.9% | -13.2% |
| Assets 1 | - | 91.31 | 149.9 | 205.5 | 303.2 | 287.3 | 307.7 |
| Book Value Per Share 2 | - | 1.720 | 1.090 | 2.270 | 1.970 | 1.660 | 1.490 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 2.71 | 14.8 | 11.5 | 12.1 | 14.6 | 17.1 |
| Capex / Sales | - | 2.86% | 10.46% | 6.12% | 5.41% | 5.57% | 5.65% |
| Announcement Date | 30/03/21 | 03/03/22 | 07/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.65
USD
Average target price
15.86
USD
Spread / Average Target
+48.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.47% | 644M | |
| +72.92% | 12.38B | |
| -19.68% | 7.92B | |
| +16.20% | 7.2B | |
| +6.78% | 5.84B | |
| +7.49% | 5.07B | |
| +23.97% | 4.53B | |
| -19.54% | 3.88B | |
| -41.54% | 2.23B | |
| +1.24% | 2.02B |
- Stock Market
- Equities
- TMCI Stock
- Financials Treace Medical Concepts, Inc.
